AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18841250 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily
Number of subjects: 375
Study 18841250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 15901456 — intervention group
Group type: EXPERIMENTAL
Intervention: G1.2-G2.2 media
Number of subjects: 599
Study 15901456 — intervention group
Group type: COMPARATOR
Intervention: GIII series sequential media
Number of subjects: 599
Study 12525796 — intervention group
Group type: EXPERIMENTAL
Intervention: PYC (200 mg/day)
Number of subjects: 27
Study 12525796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10378920 — intervention group
Group type: EXPERIMENTAL
Intervention: T1: initial speed of 6 km x h(‐1) followed by increments of 0.6 km x h(‐1) every 60 s
Number of subjects: 18
Study 10378920 — intervention group
Group type: EXPERIMENTAL
Intervention: T2: initial speed 5.6 km x h(‐1) followed by increments of 0.2 km x h(‐1) every 20 s
Number of subjects: 18
Study 10378920 — intervention group
Group type: EXPERIMENTAL
Intervention: T3: similar to T2, in the second half of phase III acceleration (S) was increased
Number of subjects: 18
Study 10378920 — intervention group
Group type: EXPERIMENTAL
Intervention: T4: like T2, at the beginning of phase III, S was increased
Number of subjects: 18
Study 9007796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 37
Study 9007796 — intervention group
Group type: COMPARATOR
Intervention: Surgical Thrombectomy (ST)
Number of subjects: 37
Study 1496125 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 12
Study 6142463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg loprazolam
Number of subjects: 40
Study 6142463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg nitrazepam
Number of subjects: 40
Study 6142463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30375339 — intervention group
Group type: EXPERIMENTAL
Intervention: BS/BS
Number of subjects: 106
Study 30375339 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ/SJ
Number of subjects: 106
Study 30375339 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ/BS
Number of subjects: 106
Study 30375339 — intervention group
Group type: EXPERIMENTAL
Intervention: BS
Number of subjects: 106
Study 30375339 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ
Number of subjects: 106
Study 29111091 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive: 30% financial incentive on eligible fruits and vegetables purchased using food benefits
Number of subjects: 265
Study 29111091 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction: not allowed to buy sugar-sweetened beverages, sweet baked goods, or candies with food benefits
Number of subjects: 265
Study 29111091 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus Restriction
Number of subjects: 265
Study 29111091 — intervention group
Group type: COMPARATOR
Intervention: Control: no incentive/restriction
Number of subjects: 265
Study 27280961 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 207
Study 27280961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 25831651 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 60
Study 25831651 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 60
Study 22575291 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT and stent grafting of the proximal tear
Number of subjects: 61
Study 22575291 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 61
Study 22129214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once‐daily
Number of subjects: 8113
Study 22129214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study 18633041 — intervention group
Group type: EXPERIMENTAL
Intervention: RM group (n = 25)
Number of subjects: 100
Study 18633041 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-NIV group (n = 25)
Number of subjects: 100
Study 18633041 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV group (n = 25)
Number of subjects: 100
Study 18633041 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 100
Study 18633041 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV groups on postoperative day 2
Number of subjects: 100
Study 18633041 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups on postoperative day 7
Number of subjects: 100
Study 16194048 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea pressed juice
Number of subjects: 40
Study 16194048 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 40
Study 12022239 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 receptor antagonist)
Number of subjects: 86
Study 12022239 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta1-adrenergic receptor blocker)
Number of subjects: 86
Study 10639684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 32
Study 10639684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg daily for 1 year)
Number of subjects: 40
Study 7491227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1780618 — intervention group
Group type: COMPARATOR
Intervention: PGE2 administration for cervical maturation
Number of subjects: 0
Study 1780618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin-induced maturation
Number of subjects: 0
Study 7039244 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin treatment
Number of subjects: 28
Study 7039244 — intervention group
Group type: COMPARATOR
Intervention: Intermittent heparin treatment
Number of subjects: 28
Study 7039244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both continuous and intermittent heparin treatment
Number of subjects: 28
Study 30346226 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT)
Number of subjects: 41
Study 30346226 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (TAU)
Number of subjects: 41
Study 31475383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (not specified)
Number of subjects: 0
Study 31475383 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 27797925 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 27797925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: %CDT
Number of subjects: 272
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 272
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: AST:ALT > 2
Number of subjects: 272
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT, MCV, %CDT
Number of subjects: 272
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV
Number of subjects: 272
Study 26110815 — intervention group
Group type: EXPERIMENTAL
Intervention: AST, ALT, AST:ALT ratio
Number of subjects: 272
Study 23134272 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy and guided visual imagery
Number of subjects: 40
Study 21294797 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 42
Study 21294797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 42
Study 19901502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored diabetic education
Number of subjects: 60
Study 19901502 — intervention group
Group type: COMPARATOR
Intervention: Group diabetic education (control)
Number of subjects: 60
Study 16675324 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-agonist asthma control scale derived from administrative data
Number of subjects: 2250
Study 16675324 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-agonist asthma control scale
Number of subjects: 2250
Study 15327427 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D SSFP imaging with slab-selective inversion prepulse
Number of subjects: 16
Study 15327427 — intervention group
Group type: COMPARATOR
Intervention: SSFP without magnetization preparation
Number of subjects: 16
Study 15327427 — intervention group
Group type: COMPARATOR
Intervention: SSFP with non-slab-selective inversion
Number of subjects: 16
Study 10903238 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (maintenance prednisone dose for 6 months)
Number of subjects: 38
Study 10903238 — intervention group
Group type: COMPARATOR
Intervention: Demand group (withdrawn from prednisone at a rate of 5 mg per week)
Number of subjects: 38
Study 10903238 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group
Number of subjects: 38
Study 10903238 — intervention group
Group type: COMPARATOR
Intervention: Demand group
Number of subjects: 38
Study 9138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline (U-62066E) 1.6 micrograms kg‐1, i.m.
Number of subjects: 6
Study 9138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline (U-62066E) 4.0 micrograms kg‐1, i.m.
Number of subjects: 6
Study 9138682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8161669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day for 7 days
Number of subjects: 6
Study 8161669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3531309 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (b.i.d.)
Number of subjects: 605
Study 3531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night
Number of subjects: 605
Study 3531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 605
Study 29730458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone‐anchored annular closure device (n=272 participants)
Number of subjects: 554
Study 29730458 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=278 participants)
Number of subjects: 554
Study 27895602 — intervention group
Group type: EXPERIMENTAL
Intervention: mBA + usual psychiatric rehabilitation
Number of subjects: 47
Study 27895602 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 47
Study 25915745 — intervention group
Group type: EXPERIMENTAL
Intervention: XpertMTB/RIF
Number of subjects: 4088
Study 25915745 — intervention group
Group type: COMPARATOR
Intervention: Sputum smear examination
Number of subjects: 4088
Study 23800717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol
Number of subjects: 132
Study 23800717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 21742556 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 307
Study 21742556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 19833454 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual 200microg misoprostol with 20UI intravenous oxytocin
Number of subjects: 250
Study 19833454 — intervention group
Group type: COMPARATOR
Intervention: only oxytocin at the same dose
Number of subjects: 250
Study 16706761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid wound dressing (Avery H2460)
Number of subjects: 16
Study 16706761 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (Fucidine cream with Cutiplast sterile dressing)
Number of subjects: 16
Study 15062699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision technique for total hip arthroplasty
Number of subjects: 0
Study 15062699 — intervention group
Group type: COMPARATOR
Intervention: Traditional incision technique for total hip arthroplasty
Number of subjects: 0
Study 11305006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (5 g administered for 3 days)
Number of subjects: 504
Study 11305006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 504
Study 8994468 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA ligated
Number of subjects: 34
Study 8994468 — intervention group
Group type: COMPARATOR
Intervention: DPA preserved
Number of subjects: 34
Study 7661144 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid
Number of subjects: 24
Study 7661144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% phosphoric acid
Number of subjects: 24
Study 7661144 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% phosphoric acid
Number of subjects: 24
Study 2767062 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal treadmill walking at -20 degrees C for 8 minutes
Number of subjects: 20
Study 2767062 — intervention group
Group type: COMPARATOR
Intervention: Submaximal treadmill walking at normal room temperature for 8 minutes
Number of subjects: 20
Study 2767062 — intervention group
Group type: COMPARATOR
Intervention: Submaximal treadmill walking at 0 degrees C for 8 minutes
Number of subjects: 20
Study 2767062 — intervention group
Group type: COMPARATOR
Intervention: Submaximal treadmill walking at -20 degrees C for 17 minutes
Number of subjects: 20
Study 326237 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% vancomycin gel applied topically using pre-trimmed plastic trays for 5 minutes every morning in school.
Number of subjects: 268
Study 326237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vancomycin treatment).
Number of subjects: 268
Study 30556275 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplasticized gutta‐percha (E&Q system)
Number of subjects: 20
Study 30556275 — intervention group
Group type: COMPARATOR
Intervention: GuttaFlow2
Number of subjects: 20
Study 26559712 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS (n = 147)
Number of subjects: 296
Study 26559712 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail (n = 149)
Number of subjects: 296
Study 25809378 — intervention group
Group type: EXPERIMENTAL
Intervention: CJP (Criminal Justice Prompted)
Number of subjects: 434
Study 25809378 — intervention group
Group type: COMPARATOR
Intervention: Not CJP (Not Prompted by Criminal Justice)
Number of subjects: 434
Study 24372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit speech and language therapy with visual support (Shape Coding)
Number of subjects: 14
Study 24372884 — intervention group
Group type: COMPARATOR
Intervention: Waiting controls (no therapy during Phase 1)
Number of subjects: 14
Study 24372884 — intervention group
Group type: COMPARATOR
Intervention: Waiting controls (after receiving therapy in Phase 2)
Number of subjects: 14
Study 24372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (therapy and waiting controls)
Number of subjects: 14
Study 22289695 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention (24-week program)
Number of subjects: 48
Study 22289695 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 48
Study 22289695 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 48
Study 20134096 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave (SW) therapy
Number of subjects: 8
Study 20134096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18391039 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg daily dose in HIV- and HBV-coinfected patients
Number of subjects: 0
Study 18391039 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 1 mg daily dose in HBV-monoinfected patients
Number of subjects: 0
Study 18391039 — intervention group
Group type: COMPARATOR
Intervention: Comparison of entecavir pharmacokinetics between HIV- and HBV-coinfected and HBV-monoinfected patients
Number of subjects: 0
Study 16570431 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (early acupuncture group)
Number of subjects: 0
Study 16570431 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with far infrared ray (group B)
Number of subjects: 0
Study 16570431 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture after 7 days (group C)
Number of subjects: 0
Study 12520628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered with a high-fat meal
Number of subjects: 18
Study 12520628 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered fasting
Number of subjects: 18
Study 12520628 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered in solution
Number of subjects: 18
Study 11221076 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock waves alone (56 patients)
Number of subjects: 481
Study 11221076 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock waves and calcioantagonist (324 patients)
Number of subjects: 481
Study 11221076 — intervention group
Group type: COMPARATOR
Intervention: Calcioantagonist alone (101 patients)
Number of subjects: 481
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (beta‐carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 15 mg)
Number of subjects: 756
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements (zinc, 20 mg and selenium, 100 micrograms)
Number of subjects: 756
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements associated with vitamins
Number of subjects: 756
Study 9433680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral supplementation (trace elements)
Number of subjects: 756
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements
Number of subjects: 756
Study 9433680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 756
Study 8270292 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 58
Study 8270292 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg on alternate days
Number of subjects: 58
Study 8270292 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (single dose)
Number of subjects: 58
Study 3304837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg/day iv
Number of subjects: 86
Study 3304837 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 86
Study 3304837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/day iv
Number of subjects: 86
Study 29863459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specialist vocational rehabilitation (VR) delivered by occupational therapists (OTs) in the community.
Number of subjects: 78
Study 29863459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 78
Study 29863459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specialist vocational rehabilitation (VR)
Number of subjects: 78
Study 27500175 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 105
Study 27500175 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 105
Study 27500175 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 105
Study 24682207 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.9 mg/kg, equivalent to 200 mg or 2 espressos for a 70-kg adult)
Number of subjects: 30
Study 24682207 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30
Study 22075171 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 18668
Study 22075171 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 18668
Study 20088993 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty stenting (CAS)
Number of subjects: 0
Study 20088993 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 18177726 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant (0.5, 2, 4, and 6 mg once per day)
Number of subjects: 0
Study 18177726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16188812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) at 200 mg/kg, repeated doses of 200, 100, and 100 mg/kg at 6-12 h intervals, maximum of four doses if OI deteriorated by >2 from baseline
Number of subjects: 61
Study 16188812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 61
Study 14759108 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture (IRO)
Number of subjects: 90
Study 14759108 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprosthetic surgery to enlarge the denture‐bearing area (PPS)
Number of subjects: 90
Study 14759108 — intervention group
Group type: COMPARATOR
Intervention: Construction of a new set of dentures (CD)
Number of subjects: 90
Study 11068962 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8888089 — intervention group
Group type: EXPERIMENTAL
Intervention: Procardia XL
Number of subjects: 15
Study 8888089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalat CC
Number of subjects: 15
Study 10147473 — intervention group
Group type: EXPERIMENTAL
Intervention: Colfosceril palmitate (synthetic surfactant)
Number of subjects: 1237
Study 10147473 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 1237
Study 3125575 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0
Study 3125575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 3125575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 0
Study 29525494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 0
Study 27487342 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH‐1‐37 (10 µg, 20 µg, 40 µg)
Number of subjects: 33
Study 27487342 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH‐1‐34 (20 µg)
Number of subjects: 33